Welcome to our dedicated page for Promis Neuroscie news (Ticker: PMN), a resource for investors and traders seeking the latest updates and insights on Promis Neuroscie stock.
Promis Neurosciences (PMN) is a clinical-stage biotechnology company pioneering precision antibody therapies targeting toxic misfolded proteins in neurodegenerative diseases. This page provides investors and researchers with timely updates on PMN's scientific advancements, clinical trial progress, and strategic developments.
Access comprehensive coverage of material events including regulatory milestones, research publications, and partnership announcements. Our curated news collection helps stakeholders track PMN's progress in developing treatments for Alzheimer's, ALS, and related disorders through its proprietary ProMIS™ discovery platform.
Key updates include clinical trial phase transitions, intellectual property developments, and peer-reviewed data disclosures. Bookmark this page for direct access to verified press releases and objective analysis of PMN's position in the neurodegenerative therapeutics landscape.
ProMIS Neurosciences (NASDAQ: PMN) has received approval from its Data and Safety Monitoring Board (DSMB) to advance to the final dose escalation cohort in its Phase 1b PRECISE-AD clinical trial of PMN310 for Alzheimer's disease treatment. The trial has shown no cases of amyloid-related imaging abnormalities (ARIA) to date through Cohort 2.
The study, designed to enroll 128 patients, is proceeding from 10 mg/kg to 20 mg/kg dosing in the final cohort. The company remains on schedule to report 6-month interim data in Q2 2026 and 12-month top-line results in Q4 2026. PMN310 is specifically engineered to target toxic oligomers while avoiding amyloid plaque, potentially offering a safer treatment approach for Alzheimer's disease.
ProMIS Neurosciences (NASDAQ: PMN) reported significant progress in Q2 2025, highlighted by the FDA Fast Track Designation for PMN310, their lead Alzheimer's disease treatment candidate. The PRECISE-AD Phase 1b trial has achieved over 50% enrollment of planned 128 patients, with notably zero cases of ARIA (amyloid-related imaging abnormalities) and no dropouts, suggesting a favorable safety profile.
The company significantly strengthened its financial position, raising $21.6 million in gross proceeds in July 2025. Q2 financial results showed cash and equivalents of $4.5 million, with R&D expenses increasing to $8.7 million from $1.6 million year-over-year, primarily due to the PRECISE-AD trial. The company expects to report 6-month blinded interim results in Q2 2026 and final topline results in Q4 2026.
ProMIS Neurosciences (NASDAQ: PMN) will present at the 2025 Alzheimer's Association International Conference in Toronto, showcasing their PRECISE-AD trial and EpiSelect™ platform. The Phase 1b trial of PMN310, designed to target toxic amyloid-beta oligomers in Alzheimer's Disease, has reached over 50% enrollment of its planned 128 patients.
Key highlights include the FDA Fast Track designation for PMN310, no observed cases of amyloid-related imaging abnormalities (ARIA), and DSMB approval to proceed to the second dose level. The company expects six-month interim data in Q2 2026 and topline results by Q4 2026.
ProMIS Neurosciences (NASDAQ: PMN), a clinical-stage biotech company focused on neurodegenerative diseases, has secured $12 million in total financing through two components: a $3 million private placement of warrants and $9 million from the exercise of existing warrants.
The new warrants were sold at $0.1875 per share through a PIPE financing, with an exercise price of $1.25 and a five-year expiration term. The financing, expected to close on July 29, 2025, includes participation from existing investors like Ally Bridge Group. Proceeds will support the clinical development of PMN310, the company's lead therapeutic candidate, and general corporate expenses.
ProMIS Neurosciences (NASDAQ: PMN), a clinical-stage biotech company focused on neurodegenerative diseases, has secured total financing of $9.2 million through multiple channels. This includes a $2.4 million private placement through warrant sales at $0.1875 per share, $6.8 million from existing warrant exercises, and $0.8 million from a registered offering.
The new warrants have an exercise price of $1.25 per share with a five-year expiration term. The private placement, expected to close on July 24, 2025, received support from an existing healthcare-focused institutional investor. Funds will support the clinical development of PMN310, the company's lead therapeutic candidate, and general corporate expenses.
ProMIS Neurosciences (NASDAQ: PMN), a clinical-stage biotech company focused on neurodegenerative diseases, has announced a $0.8 million registered direct offering through the sale of pre-funded warrants. The company will issue 984,736 pre-funded warrants at $0.8124 per share to an existing healthcare-focused institutional investor.
The warrants will have a nominal exercise price of $0.0001 per share and will be immediately exercisable. The offering is expected to close around July 24, 2025. Proceeds will support the clinical development of PMN310, the company's lead therapeutic candidate, and provide working capital for general corporate expenses.
ProMIS Neurosciences (NASDAQ: PMN) has received Fast Track designation from the FDA for PMN310, its lead therapeutic candidate for Alzheimer's disease treatment. This designation accelerates development for therapies addressing serious unmet medical needs and enables enhanced FDA engagement.
PMN310 is designed to selectively target toxic forms of amyloid-beta, potentially offering reduced side effects compared to current treatments, particularly regarding ARIA (brain swelling and bleeding). The company is currently conducting the PRECISE-AD Phase 1b trial, with interim data expected in Q2 2026 and final results in Q4 2026.
ProMIS Neurosciences (Nasdaq: PMN) reported its 2024 financial results and key developments. The company successfully initiated a 100-patient Phase 1b clinical trial for PMN310, their lead antibody candidate for Alzheimer's disease. The PRECISE-AD trial is currently enrolling and dosing patients across 22 US sites, with interim results expected in 1H 2026 and topline results by end of 2026.
Financial highlights include cash position of $13.3 million as of December 31, 2024, and completion of a PIPE financing providing $30.3 million upfront with potential for additional $92.4 million from warrant exercises. The company reported net income of $2.8 million for 2024, primarily due to a $22.6 million gain from warrant liability changes. R&D expenses increased to $10.6 million, while G&A expenses slightly decreased to $6.2 million.
The company expanded its IP portfolio with 23 newly granted patents, including 17 for PMN310. They also advanced programs in ALS and Parkinson's disease, identifying PMN440 as a lead vaccine candidate for multiple synucleopathies.
FAQ
What is the current stock price of Promis Neuroscie (PMN)?
What is the market cap of Promis Neuroscie (PMN)?
